Chief Executive Officer of AMPIO Pharmaceuticals points to upcoming clinical trial results and key milestones Print E-mail
By Staff and Wire Reports   
Tuesday, 28 February 2012 06:39
On Monday, shares of AMPIO Pharmaceuticals (NASDAQ:AMPE) rose 5.13% on nearly three times the average daily volume after word began to spread that 2012 is a year filled with key catalysts for the Colorado based firm. 

Earlier in the year, AMPE shares traded as high as $9.27 after investors first learned about the company’s novel approach to introducing drugs with huge unmet needs-- each with multi-billion dollar markets-- more efficiently and cost effectively than traditional biotechs.

In an exclusive video interview, Michael Macaluso, the Founder and Chief Executive Officer of AMPIO Pharmaceuticals tells investors that if 2011 was the firm’s year to get their drug candidates into clinical trials, then 2012 will be the year to prove that they really work. “We expect very good results and believe they will be the stepping stone for this company,” explains Macaluso.  “We hope to move into the future with a much higher valuation.”

During the interview, Macaluso reiterates and clarifies some previous guidance about several key milestones set to occur within the first half of this year and technically it appears that shares may be attempting to recover from their recent bottom level lows. Clinical trial results for one of the company’s flagship drugs are expected shortly.

Ampio's product pipeline includes new uses for approved drugs and new molecular entities ('NMEs') for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The company's product pipeline includes: Optina(TM) for diabetic retinopathy, Vasaloc(TM) for diabetic nephropathy, and Ampion(TM) for chronic inflammation.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus